Gordon Robb, a former vice-president of a biotech company, is taking part in a new British Heart Foundation-funded clinical trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results